These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 15377799

  • 1. Clinical and familial correlates of tardive dyskinesia in India and Israel.
    Bhatia T, Sabeeha MR, Shriharsh V, Garg K, Segman RH, Uriel HL, Strous R, Nimgaonkar VL, Bernard L, Deshpande SN.
    J Postgrad Med; 2004; 50(3):167-72; discussion 172. PubMed ID: 15377799
    [Abstract] [Full Text] [Related]

  • 2. The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients.
    Go CL, Rosales RL, Caraos RJ, Fernandez HH.
    Parkinsonism Relat Disord; 2009 Nov; 15(9):655-9. PubMed ID: 19346155
    [Abstract] [Full Text] [Related]

  • 3. Tardive dyskinesia and impaired glucose tolerance.
    Chong SA, Mythily, Lum A, Huak CY, Kane J.
    Hum Psychopharmacol; 2002 Aug; 17(6):305-7. PubMed ID: 12404676
    [Abstract] [Full Text] [Related]

  • 4. Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions.
    Dean CE, Kuskowski MA, Caligiuri MP.
    J Clin Psychopharmacol; 2006 Dec; 26(6):560-5. PubMed ID: 17110811
    [Abstract] [Full Text] [Related]

  • 5. Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study.
    Lerner V, Kaptsan A, Miodownik C, Kotler M.
    Clin Neuropharmacol; 1999 Dec; 22(4):241-3. PubMed ID: 10442256
    [Abstract] [Full Text] [Related]

  • 6. Tardive dyskinesia in India: a prevalence study.
    Doongaji DR, Jeste DV, Jape NM, Sheth AS, Apte JS, Vahia VN, Desai AB, Vahora SA, Thatte S, Vevaina T, Bharadwaj J.
    J Clin Psychopharmacol; 1982 Oct; 2(5):341-4. PubMed ID: 6127352
    [Abstract] [Full Text] [Related]

  • 7. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.
    Lohmann PL, Bagli M, Krauss H, Müller DJ, Schulze TG, Fangerau H, Ludwig M, Barkow K, Held T, Heun R, Maier W, Rietschel M, Rao ML.
    Pharmacopsychiatry; 2003 Oct; 36(2):73-8. PubMed ID: 12734765
    [Abstract] [Full Text] [Related]

  • 8. White matter abnormalities in schizophrenia patients with tardive dyskinesia: a diffusion tensor image study.
    Bai YM, Chou KH, Lin CP, Chen IY, Li CT, Yang KC, Chou YH, Su TP.
    Schizophr Res; 2009 Apr; 109(1-3):167-81. PubMed ID: 19261444
    [Abstract] [Full Text] [Related]

  • 9. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK, Zalar B, Breskvar K, Dolzan V.
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [Abstract] [Full Text] [Related]

  • 10. Focus on lower risk of tardive dyskinesia with atypical antipsychotics.
    Nasrallah HA.
    Ann Clin Psychiatry; 2006 Nov; 18(1):57-62. PubMed ID: 16517454
    [Abstract] [Full Text] [Related]

  • 11. [Epidemiology of tardive dyskinesias in the Maghreb].
    Moussaoui D, Douki S, Bentounsi B, Otarid A, Chorfi M, Mamou A, Benamor L.
    Encephale; 1988 Sep; 14 Spec No():203-8. PubMed ID: 2905647
    [Abstract] [Full Text] [Related]

  • 12. Prevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophrenia.
    Achalia RM, Chaturvedi SK, Desai G, Rao GN, Prakash O.
    Asian J Psychiatr; 2014 Jun; 9():31-5. PubMed ID: 24813033
    [Abstract] [Full Text] [Related]

  • 13. [Manganese superoxide dismutase gene (MnSOD) polimorphism in schizophrenics with tardive dyskinesia from central Poland].
    Gałecki P, Pietras T, Szemraj J.
    Psychiatr Pol; 2006 Jun; 40(5):937-48. PubMed ID: 17217237
    [Abstract] [Full Text] [Related]

  • 14. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
    Fu Y, Fan CH, Deng HH, Hu SH, Lv DP, Li LH, Wang JJ, Lu XQ.
    Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
    [Abstract] [Full Text] [Related]

  • 15. No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia.
    Lee HJ, Kang SG, Choi JE, Paik JW, Kim YK, Kim SH, Lee MS, Joe SH, Jung IK, Kim L.
    Neuropsychobiology; 2007 Mar; 55(1):47-51. PubMed ID: 17556853
    [Abstract] [Full Text] [Related]

  • 16. "Positive" and "negative" movement disorders in schizophrenia.
    Sandyk R, Kay SR.
    Int J Neurosci; 1992 Oct; 66(3-4):143-51. PubMed ID: 1305614
    [Abstract] [Full Text] [Related]

  • 17. Diabetes is not a risk factor for tardive dyskinesia: a retrospective observational study.
    Raja M, Azzoni A.
    Hum Psychopharmacol; 2002 Jan; 17(1):61-3. PubMed ID: 12404708
    [Abstract] [Full Text] [Related]

  • 18. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
    Dolzan V, Serretti A, Mandelli L, Koprivsek J, Kastelic M, Plesnicar BK.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug 01; 32(6):1562-6. PubMed ID: 18573584
    [Abstract] [Full Text] [Related]

  • 19. The prevalence of tardive dyskinesia.
    Woerner MG, Kane JM, Lieberman JA, Alvir J, Bergmann KJ, Borenstein M, Schooler NR, Mukherjee S, Rotrosen J, Rubinstein M.
    J Clin Psychopharmacol; 1991 Feb 01; 11(1):34-42. PubMed ID: 1674949
    [Abstract] [Full Text] [Related]

  • 20. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial.
    Lee JG, Shin BS, Lee YC, Park SW, Kim YH.
    Psychiatry Clin Neurosci; 2007 Oct 01; 61(5):509-14. PubMed ID: 17875029
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.